- Home
- CLEU vs UBX Comparison
CLEU vs UBX Comparison
Compare CLEU & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLEU
- UBX
- Stock Information
- Founded
- CLEU 2011
- UBX 2009
- Country
- CLEU China
- UBX United States
- Employees
- CLEU N/A
- UBX N/A
- Industry
- CLEU Other Consumer Services
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- CLEU Real Estate
- UBX Health Care
- Exchange
- CLEU Nasdaq
- UBX Nasdaq
- Market Cap
- CLEU 20.0M
- UBX 16.2M
- IPO Year
- CLEU 2020
- UBX 2018
- Fundamental
- Price
- CLEU $2.05
- UBX $1.00
- Analyst Decision
- CLEU
- UBX Strong Buy
- Analyst Count
- CLEU 0
- UBX 3
- Target Price
- CLEU N/A
- UBX $5.33
- AVG Volume (30 Days)
- CLEU 58.7K
- UBX 139.9K
- Earning Date
- CLEU 01-01-0001
- UBX 04-22-2025
- Dividend Yield
- CLEU N/A
- UBX N/A
- EPS Growth
- CLEU N/A
- UBX N/A
- EPS
- CLEU N/A
- UBX N/A
- Revenue
- CLEU $2,413,409.00
- UBX N/A
- Revenue This Year
- CLEU N/A
- UBX N/A
- Revenue Next Year
- CLEU N/A
- UBX N/A
- P/E Ratio
- CLEU N/A
- UBX N/A
- Revenue Growth
- CLEU N/A
- UBX N/A
- 52 Week Low
- CLEU $0.05
- UBX $0.85
- 52 Week High
- CLEU $7.90
- UBX $3.10
- Technical
- Relative Strength Index (RSI)
- CLEU 57.70
- UBX 42.00
- Support Level
- CLEU $1.43
- UBX $0.93
- Resistance Level
- CLEU $1.71
- UBX $1.03
- Average True Range (ATR)
- CLEU 0.16
- UBX 0.08
- MACD
- CLEU 0.03
- UBX 0.04
- Stochastic Oscillator
- CLEU 100.00
- UBX 81.57
About CLEU China Liberal Education Holdings Limited
China Liberal Education Holdings Ltd is an educational service provider operating in China. The company's operating segment includes Sino-foreign Jointly Managed Academic Programs, textbooks and course material sales, Overseas Study Consulting Services, Technological Consulting Services for Smart Campus Solutions and Tailored Job Readiness Training Services. Geographically, it derives revenue from China.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.